Compare Illumina, Inc. (ILMN) vs New York Times Co (NYT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs New York Times Co — how do they compare? Illumina, Inc. trades at $274.69 (market cap $39.95B), while New York Times Co trades at $65.93 (market cap $10.74B). The key difference: Illumina, Inc. is far larger — about 3.7× New York Times Co's market cap, and New York Times Co pays a 1.38% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Illumina, Inc. for 83 Days and New York Times Co for 81 Days on average.
| ILMN | NYT | |
|---|---|---|
Market Cap | $39.95B | $10.74B |
Volume | 3,169,503 | 2,096,352 |
Sector | Health | Media |
52-Week High | $293.69 | $85.86 |
52-Week Low | $91.00 | $54.66 |
Typical Hold Time | 83 Days | 81 Days |
Enterprise Value | $41.31B | $10.14B |
Dividend Yield | — | 1.38% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $271.02, up 1.22% and near its 52-week high, reflecting strong momentum. The stock exhibits a bullish technical trend with recent earnings beats and a positive analyst consensus. Revenue for 2025 was $4.34B with net income of $850M, marking a significant profit margin recovery. Cash flow from operations remains robust at $1.08B, supporting financial stability. Inclusion in the S&P 500 and focus on AI-driven genomics growth are key catalysts.
Outlook is positive given earnings momentum and strategic initiatives, but risks include valuation premiums and competitive pressures. The stock offers growth exposure to genomic innovation, though investors should monitor execution on AI integration and margin sustainability. Analyst price targets suggest moderate upside from current levels, with consensus at $241.00.
The New York Times Company (NYSE: NYT) trades at $65.64, up 1.14% today, with a bullish technical signal and strong fundamentals. Revenue grew from $2.3B in 2022 to $2.8B in 2025, with net income margin expanding to 12.17%. Recent earnings beats and a declared $0.23 dividend highlight operational strength, though a shareholder lawsuit presents headline risk.
Outlook is positive given consistent earnings outperformance and analyst consensus target of $84.00, implying 28% upside. Key risks include the pending lawsuit's impact on reputation and competitive pressures in digital media. Cash flow generation remains robust, supporting dividend sustainability and growth initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About New York Times Co
New York Times Co is an American media company known for publishing its flagship newspaper, The New York Times. The company also operates the International New York Times newspaper, as well as digital properties such as nytimes and various smartphone applications. Circulation of The New York Times is the source of revenue for the company, followed by print and digital advertising and its paid digital-only subscription to The New York Times. The company has a daily print circulation of over 500,000 and 1,000,000 on Sundays. The source of growth for The New York Times is its digital subscription service, which has over 1,000,000 paid users.
Read more on NYT →
